Overview

January 27-29: Forum

DIA's Global Pharmacovigilance and Risk Management Strategies Conference is a neutral event developed by regulators and industry experts discussing the updates, opportunities, and challenges alongside fresh problem-solving strategies that matter most to safety professionals.

Participant Testimonials

This PV and Risk Management conference was the best I've attended in a long time -- content was very current, and speakers provided detailed examples that helped to understand the concepts presented – Peg Fletcher, MD, PhD, President, MedAssessment, Inc.

Always a wonderful conference of some of the best minds in pharmacovigilance and risk management. Cutting edge ideas with all stakeholders included! – Jamie Wilkins, PharmD, Head, Risk Management Center of Excellence, Pfizer Inc.

Very high caliber conference with highly experienced professionals, regulators, and service providers. Great opportunity to learn new skills, understand new technologies and network with peers and vendors. Great job DIA! – Famina Hemani, Vice President, Head of Pharmacovigilance, Tourmaline Bio

Featured

Want to learn more about Global Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Who should attend?

Conference Designed for
- Benefit-risk Assessment and Communication
- Clinical Research
- Data Safety Monitoring and Analysis
- Drug Safety
- Health Outcomes
- Medical Affairs
- Medical Communications
- Medical Information
- Medical Writing
- Medical Product Safety Assessment
- Patient Engagement and Advocacy Groups
- Pharmacoepidemiology
- Pharmacovigilance
- Post-Market Studies
- Quality Assurance
- Quality Control
- Real-World Evidence Generation
- Regulatory Affairs
- Risk Management
- Safety Statistics

Program Committee

James Buchanan, PharmD President
Covilance LLC, United States
Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Worldwide Safety Officer
Bristol-Myers Squibb Company, United States
Barbara Hendrickson, DrMed, MD Clinical Associate, Pediatric Infectious Diseases
University of Chicago, United States
Scott Janiczak, PharmD, MPH Safety Evaluator, LCDR, Division of Pharmacovigilance I, OSE, CDER
FDA, United States
Mamiko Kasho Executive Director, Global PV Management Dept., Global Safety HQs
Eisai Co., Ltd., Japan
Susan Kindig, JD, MD Prior Executive Director, Medical and Drug Safety
United States
Mengchun Li, MD, MPA Senior Director, Clinical Research, Infectious Disease
Merck & Co., Inc., United States
Joseph Paradis, PharmD Associate Director for Medication Error and Risk Management Initiatives, CDER
FDA, United States
Mark Perrott, PhD Managing Partner
Axian Consulting Ltd., United Kingdom
Ranjeeta Sinvhal, MD Executive Medical Director, Medical Safety
AbbVie, United States
Bethany Van Veen Pharmacovigilance Consultant
Perspective Pharmacovigilance, United States
Representative Invited DIA, United States
Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
IQVIA, United States